NITRO-BID

Post-LOE

Sanofi

ANDAINJECTIONINJECTABLE

Approved

Feb 1990

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

NITRO-BID by Sanofi is clinical pharmacology: the principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Approved for angina pectoris due to coronary artery disease. First approved in 1990.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY: The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the…

Worked on NITRO-BID at Sanofi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

NITRO-BID

Mechanism of Action

Indications (1)